Furthermore, GMRGs like GOT2 could contribute to an in-depth understanding of the underlying mechanisms of CM and may become a new independent biomarker and target for the diagnosis and treatment of CM. The gene discussed is GOT2; the disease is cutaneous mastocytosis.